These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 33115544)

  • 1. Health Assessment Questionnaire-Disability Index (HAQ-DI) use in modelling disease progression in diffuse cutaneous systemic sclerosis: an analysis from the EUSTAR database.
    Allanore Y; Bozzi S; Terlinden A; Huscher D; Amand C; Soubrane C; Siegert E; Czirják L; Carreira PE; Hachulla E; Zanatta E; Li M; Airò P; Mendoza FA; Rosato E; Distler O;
    Arthritis Res Ther; 2020 Oct; 22(1):257. PubMed ID: 33115544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Do We Have Good Activity Indices in Systemic Sclerosis?
    Groseanu L; Petrescu S; Balanescu A; Bojinca V; Opris-Belinski D; Berghea F; Mazilu D; Saulescu I; Borangiu A; Daia-Iliescu S; Constantinescu C; Cobilinschi C; Abobului M; Negru MM; Ionescu R
    Curr Rheumatol Rev; 2022; 18(1):39-47. PubMed ID: 34517805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disability, fatigue, pain and their associates in early diffuse cutaneous systemic sclerosis: the European Scleroderma Observational Study.
    Peytrignet S; Denton CP; Lunt M; Hesselstrand R; Mouthon L; Silman A; Pan X; Brown E; Czirják L; Distler JHW; Distler O; Fligelstone K; Gregory WJ; Ochiel R; Vonk M; Ancuta C; Ong VH; Farge D; Hudson M; Matucci-Cerinic M; Balbir-Gurman A; Midtvedt Ø; Jordan AC; Stevens W; Moinzadeh P; Hall FC; Agard C; Anderson ME; Diot E; Madhok R; Akil M; Buch MH; Chung L; Damjanov N; Gunawardena H; Lanyon P; Ahmad Y; Chakravarty K; Jacobsen S; MacGregor AJ; McHugh N; Müller-Ladner U; Riemekasten G; Becker M; Roddy J; Carreira PE; Fauchais AL; Hachulla E; Hamilton J; Inanç M; McLaren JS; van Laar JM; Pathare S; Proudman S; Rudin A; Sahhar J; Coppere B; Serratrice C; Sheeran T; Veale DJ; Grange C; Trad GS; Herrick AL
    Rheumatology (Oxford); 2018 Feb; 57(2):370-381. PubMed ID: 29207002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in disability and their relationship with skin thickening, in diffuse and limited cutaneous systemic sclerosis: a retrospective cohort study.
    Peytrignet S; Manning J; Wragg E; Moore T; Samaranayaka M; Dinsdale G; Herrick AL
    Scand J Rheumatol; 2019 May; 48(3):230-234. PubMed ID: 30394164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progressive skin fibrosis is associated with a decline in lung function and worse survival in patients with diffuse cutaneous systemic sclerosis in the European Scleroderma Trials and Research (EUSTAR) cohort.
    Wu W; Jordan S; Graf N; de Oliveira Pena J; Curram J; Allanore Y; Matucci-Cerinic M; Pope JE; Denton CP; Khanna D; Distler O;
    Ann Rheum Dis; 2019 May; 78(5):648-656. PubMed ID: 30852552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tendon friction rubs in early diffuse systemic sclerosis: prevalence, characteristics and longitudinal changes in a randomized controlled trial.
    Khanna PP; Furst DE; Clements PJ; Maranian P; Indulkar L; Khanna D;
    Rheumatology (Oxford); 2010 May; 49(5):955-9. PubMed ID: 20144926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in skin score in early diffuse cutaneous systemic sclerosis are associated with changes in global disease severity.
    Zheng B; Nevskaya T; Baxter CA; Ramey DR; Pope JE; Baron M;
    Rheumatology (Oxford); 2020 Feb; 59(2):398-406. PubMed ID: 31359048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patterns and predictors of change in outcome measures in clinical trials in scleroderma: an individual patient meta-analysis of 629 subjects with diffuse cutaneous systemic sclerosis.
    Merkel PA; Silliman NP; Clements PJ; Denton CP; Furst DE; Mayes MD; Pope JE; Polisson RP; Streisand JB; Seibold JR;
    Arthritis Rheum; 2012 Oct; 64(10):3420-9. PubMed ID: 22328195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of improvement in skin fibrosis in diffuse cutaneous systemic sclerosis: a EUSTAR analysis.
    Dobrota R; Maurer B; Graf N; Jordan S; Mihai C; Kowal-Bielecka O; Allanore Y; Distler O;
    Ann Rheum Dis; 2016 Oct; 75(10):1743-8. PubMed ID: 27016052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database.
    Maurer B; Graf N; Michel BA; Müller-Ladner U; Czirják L; Denton CP; Tyndall A; Metzig C; Lanius V; Khanna D; Distler O;
    Ann Rheum Dis; 2015 Jun; 74(6):1124-31. PubMed ID: 24981642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Disability Index of the Health Assessment Questionnaire is a predictor and correlate of outcome in the high-dose versus low-dose penicillamine in systemic sclerosis trial.
    Clements PJ; Wong WK; Hurwitz EL; Furst DE; Mayes M; White B; Wigley F; Weisman M; Barr W; Moreland L; Medsger TA; Steen V; Martin RW; Collier D; Weinstein A; Lally E; Varga J; Weiner SR; Andrews B; Abeles M; Seibold JR
    Arthritis Rheum; 2001 Mar; 44(3):653-61. PubMed ID: 11263780
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive value of European Scleroderma Group Activity Index in an early scleroderma cohort.
    Nevskaya T; Baron M; Pope JE;
    Rheumatology (Oxford); 2017 Jul; 56(7):1111-1122. PubMed ID: 28340090
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cutaneous Manifestations, Clinical Characteristics, and Prognosis of Patients With Systemic Sclerosis Sine Scleroderma: Data From the International EUSTAR Database.
    Lescoat A; Huang S; Carreira PE; Siegert E; de Vries-Bouwstra J; Distler JHW; Smith V; Del Galdo F; Anic B; Damjanov N; Rednic S; Ribi C; Bancel DF; Hoffmann-Vold AM; Gabrielli A; Distler O; Khanna D; Allanore Y;
    JAMA Dermatol; 2023 Aug; 159(8):837-847. PubMed ID: 37378994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical characteristics, visceral involvement, and mortality in at-risk or early diffuse systemic sclerosis: a longitudinal analysis of an observational prospective multicenter US cohort.
    Jaafar S; Lescoat A; Huang S; Gordon J; Hinchcliff M; Shah AA; Assassi S; Domsic R; Bernstein EJ; Steen V; Elliott S; Hant F; Castelino FV; Shanmugam VK; Correia C; Varga J; Nagaraja V; Roofeh D; Frech T; Khanna D
    Arthritis Res Ther; 2021 Jun; 23(1):170. PubMed ID: 34127049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gender and ethnicity differences in patients with diffuse systemic sclerosis--analysis from three large randomized clinical trials.
    Nashid M; Khanna PP; Furst DE; Clements PJ; Maranian P; Seibold J; Postlethwaite AE; Louie JS; Mayes MD; Agrawal H; Khanna D;
    Rheumatology (Oxford); 2011 Feb; 50(2):335-42. PubMed ID: 20889574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The health assessment questionnaire (HAQ) is strongly predictive of good outcome in early diffuse scleroderma: results from an analysis of two randomized controlled trials in early diffuse scleroderma.
    Sultan N; Pope JE; Clements PJ;
    Rheumatology (Oxford); 2004 Apr; 43(4):472-8. PubMed ID: 14679295
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Skin improvement is a surrogate for favourable changes in other organ systems in early diffuse cutaneous systemic sclerosis.
    Nevskaya T; Zheng B; Baxter CA; Ramey DR; Pope JE; Baron M;
    Rheumatology (Oxford); 2020 Jul; 59(7):1715-1724. PubMed ID: 31774531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlates of the disability index of the health assessment questionnaire: a measure of functional impairment in systemic sclerosis.
    Clements PJ; Wong WK; Hurwitz EL; Furst DE; Mayes M; White B; Wigley F; Weisman M; Barr W; Moreland L; Medsger TA; Steen V; Martin R; Collier D; Weinstein A; Lally E; Varga J; Weiner S; Andrews B; Abeles M; Seibold J
    Arthritis Rheum; 1999 Nov; 42(11):2372-80. PubMed ID: 10555033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Minimal Clinically Important Differences for the Modified Rodnan Skin Score: Results from the Scleroderma Lung Studies (SLS-I and SLS-II).
    Khanna D; Clements PJ; Volkmann ER; Wilhalme H; Tseng CH; Furst DE; Roth MD; Distler O; Tashkin DP
    Arthritis Res Ther; 2019 Jan; 21(1):23. PubMed ID: 30651141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence and predictors of cutaneous manifestations during the early course of systemic sclerosis: a 10-year longitudinal study from the EUSTAR database.
    Wirz EG; Jaeger VK; Allanore Y; Riemekasten G; Hachulla E; Distler O; Airò P; Carreira PE; Tikly M; Vettori S; Balbir Gurman A; Damjanov N; Müller-Ladner U; Distler J; Li M; Häusermann P; Walker UA;
    Ann Rheum Dis; 2016 Jul; 75(7):1285-92. PubMed ID: 26232495
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.